Xanthines of the general formula: ##STR1## wherein R.sup.1 represents a straight or branched chain alkyl, alkenyl or alkynyl group of 3-6 carbon atoms, and R.sup.2 and R.sup.3, which may be the same or different, each represent hydrogen or halogen or a methyl, methoxy, nitro or trifluoromethyl group or R.sup.2 and R.sup.3 together form a methylenedioxy or ethylenedioxy group; with the proviso that R.sup.2 and R.sup.3 are not both hydrogen; and pharmacologically acceptable salts thereof with an alkali metal base or a nitrogen base containing organic base, are bronchodilators making them of value in treating asthma and vasodilators making them of interest in treating angina, hypertension, congestive heart failure and multi-infarct dementia. The compounds are also of use in combatting other conditions where inhibition of PDE type IV is thought to be beneficial. The compounds can be prepared by treating and corresponding 6-amino uracil with sodium nitrite and formic acid in an excess of formamide and adding sodium dithionate to reduce the resulting 6-amino-5-nitroso compound to give the 5,6-diamino compound that ring closes with the excess of formamide.

Laboratorios Almirall SA

Xanthine compounds and compositions, and methods of using them

A method for the treatment of cerebral vascular and neuronal degenerative disorders associated with learning, memory and cognitive dysfunctions including cerebral senility, multi-infarct dementia and senile dementia of the Alzheimer type and/or peripheral vascular disease and/or proliferative skin disease in mammals, such as humans, which comprises administering to the mammal in need of such treatment an effective amount of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine or a pharmaceutically acceptable salt thereof.

xanthine/infarction

Xanthine compounds and compositions, and methods of using them

Novel treatment

המאגר השלם ביותר של צמחי מרפא המגובה על ידי המדע